Personalized Immunoprevention and Cancer Vaccines
Advances in immunology are opening new frontiers in preventive oncology, focusing on strategies to harness the immune system to intercept cancer before it develops. Personalized immunoprevention involves tailoring vaccines or immune-based interventions to individual molecular and genetic risk profiles, targeting tumor-associated antigens or neoantigens specific to high-risk populations. The development of prophylactic cancer vaccines, such as those for virus-associated malignancies (e.g., HPV and hepatitis B), provides a model for extending immunoprevention to non-viral cancers through emerging peptide, mRNA, and dendritic cell vaccine platforms. Immune checkpoint modulation and adoptive immune therapies are being explored as preventive approaches in individuals with precancerous lesions or high-risk genetic mutations. Biomarker-guided immune monitoring enables real-time assessment of immune response and efficacy, facilitating adaptive immunoprevention strategies. Ethical, regulatory, and safety considerations, including long-term immune surveillance and risk-benefit assessment, are critical in clinical implementation. Translational research pipelines integrate preclinical models, early-phase clinical trials, and population-level studies to validate vaccine effectiveness and guide deployment strategies. Integration with public health initiatives, lifestyle interventions, and conventional screening programs ensures a multi-layered preventive framework. By leveraging precision immunology and vaccine technology, personalized immunoprevention represents a paradigm shift toward proactive cancer interception, offering the potential to significantly reduce incidence and improve population health outcomes.